Transcription of Press release Third quarter 2021
{{id}} {{{paragraph}}}
Example: bankruptcy
Press release Third quarter 2021
Press release Third quarter 2021 Q3 Results summary Total and Adjusted results Quarterly performance YTD performance Financial information Issued: Wednesday, 27 october 2021, London, 1 Issued: Wednesday, 27 october 2021, London GSK delivers strong Q3 sales of billion +5% AER, +10% CER Total EPS -7% AER, +3% CER; Adjusted EPS +3% AER, +10% CER 2021 full year EPS guidance improved Highlights Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand Pharmaceuticals billion +5% AER, +10% CER with growth in New and Specialty medicines +24% CER; Respiratory +33% CER; Immuno-inflammation +32% CER ex-COVID-19 solutions; Oncology +34% CER; total HIV +8% CER Vaccines billion +7% AER, +13% CER with Shingrix 502 million +41% CER COVID-19 solutions sales 209 million; Xevudy 114 million and pandemic adjuvant 94 million Consumer Healthcare billion +3% AER, +8% CER (+10% excluding divestments/brands under rev)
Issued: Wednesday, 27 October 2021, London, U.K. 3 Operating performance – Q3 2021 Turnover Q3 2021 £m Growth £% Growth CER% Pharmaceuticals 4,397 5 10 Vaccines 2,174 7 13 Consumer Healthcare 2,506 3 8 Group turnover 9,077 5 10 Group turnover was £9,077 million in the quarter, up 5% AER, 10% CER.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: